These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 30758919

  • 21. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D.
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [Abstract] [Full Text] [Related]

  • 22. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.
    Shen Z, Gillen M, Tieu K, Nguyen M, Harmon E, Wilson DM, Kerr B, Lee CA.
    Drug Des Devel Ther; 2016; 10():3509-3517. PubMed ID: 27826183
    [Abstract] [Full Text] [Related]

  • 23. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Almeida L, Falcão A, Vaz-da-Silva M, Nunes T, Santos AT, Rocha JF, Neta C, Macedo T, Fontes-Ribeiro C, Soares-da-Silva P.
    Eur J Clin Pharmacol; 2008 Oct; 64(10):961-6. PubMed ID: 18679669
    [Abstract] [Full Text] [Related]

  • 24. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.
    Flora DR, Rettie AE, Brundage RC, Tracy TS.
    J Clin Pharmacol; 2017 Mar; 57(3):382-393. PubMed ID: 27539372
    [Abstract] [Full Text] [Related]

  • 25. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
    Walker G, Mandagere A, Dufton C, Venitz J.
    Br J Clin Pharmacol; 2009 May; 67(5):527-34. PubMed ID: 19552747
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects.
    Desai A, Yamazaki T, Dietz AJ, Kowalski D, Lademacher C, Pearlman H, Akhtar S, Townsend R.
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):86-92. PubMed ID: 27278712
    [Abstract] [Full Text] [Related]

  • 32. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
    Moore KT, Byra W, Vaidyanathan S, Natarajan J, Ariyawansa J, Salih H, Turner KC.
    Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
    [Abstract] [Full Text] [Related]

  • 33. Puerarin offsets the anticoagulation effect of warfarin in rats by inducing rCyps, upregulating vitamin K epoxide reductase and inhibiting thrombomodulin.
    Ge B, Zhang Z, Lam TT, Zuo Z.
    Biopharm Drug Dispos; 2017 Jan; 38(1):33-49. PubMed ID: 27925234
    [Abstract] [Full Text] [Related]

  • 34. New urate-lowing therapies.
    Abhishek A.
    Curr Opin Rheumatol; 2018 Mar; 30(2):177-182. PubMed ID: 29251661
    [Abstract] [Full Text] [Related]

  • 35. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS.
    J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
    Albrecht D, Turakhia MP, Ries D, Marbury T, Smith W, Dillon D, Milner PG, Midei MG.
    Thromb Haemost; 2017 Nov; 117(11):2026-2033. PubMed ID: 28933798
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
    Kosoglou T, Zhu Y, Xuan F, Black L, Johnson-Levonas AO, Martinho M, Statkevich P, Cutler DL.
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1509-16. PubMed ID: 22476387
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects.
    Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, Matthias A, Lehmann RP, McLachlan AJ.
    Br J Clin Pharmacol; 2010 May; 69(5):508-15. PubMed ID: 20573086
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.